We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Nanodiamonds Dramatically Boost Immunoassay Sensitivity

By LabMedica International staff writers
Posted on 08 Dec 2020
Incorporation of a specific class of nanodiamond into lateral flow immunoassays was shown to increase the sensitivity of this method by at least five orders of magnitude.

Nanodiamonds or diamond nanoparticles are diamonds with a size below one micrometer, which are commercially produced by detonation synthesis. More...
A class of fluorescent nanodiamonds containing nitrogen-vacancy defects has attractive properties for in vitro biosensing, including brightness, low cost, and selective manipulation of their emission.

Investigators at University College London (United Kingdom) studied fluorescent nanodiamonds as an ultrasensitive label for in vitro diagnostics, using a microwave field to modulate emission intensity and frequency-domain analysis to separate the signal from background autofluorescence, which typically limits sensitivity. Since the quantum properties of fluorescent nanodiamonds allow their emission to be selectively modulated, the signal can be fixed at a set frequency using a microwave field and can be efficiently separated from the background fluorescence.

Using lateral flow immunoassay as the experimental system, the investigators achieved a detection limit of 8.2 × 10−19 molar for a biotin–avidin model, 100,000 times more sensitive than that obtained using gold nanoparticles. Furthermore, single-copy detection of HIV-1 RNA could be achieved with the addition of a 10-minute isothermal recombinase polymerase amplification step. This method was then demonstrated using a clinical plasma sample with an extraction step.

Senior author Dr. Rachel McKendry, professor of biomedical nanotechnology at University College London, said, "Our proof-of-concept study shows how quantum technologies can be used to detect ultralow levels of virus in a patient sample, enabling much earlier diagnosis. We have focused on the detection of HIV, but our approach is very flexible and can be easily adapted to other diseases and biomarker types. We are working on adapting our approach to COVID-19. We believe that this transformative new technology will benefit patients and protect populations from infectious diseases."

The next step will be to adapt the assay for use a smartphone or portable fluorescence reader, which would allow the test to be performed in low-resource settings.

The use of nanodiamonds to increase the sensitivity of lateral flow assays was described in the November 25, 2020, online edition of the journal Nature.

Related Links:
University College London


Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
ESR Analyzer
miniiSED™
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.